Cyclic-AMP production by polymorphonuclear leukocytes in psychiatric disorders

Area of Science:

• Neuroscience
• Biochemistry
• Psychiatry

Background:

• Altered cyclic adenosine monophosphate (cAMP) signaling has been implicated in psychiatric disorders.
• Polymorphonuclear leukocytes (PMNs) offer a potential peripheral model for studying cellular responses in these conditions.

Purpose of the Study:

• To investigate and compare the cAMP responses to specific receptor agonists in PMNs from individuals with schizophrenia, major depressive disorder, and healthy controls.
• To determine if cAMP signaling in PMNs can serve as a state-dependent or state-independent biomarker for schizophrenia or major depressive disorder.

Main Methods:

• Measurement of intracellular cAMP levels in PMNs.
• Stimulation of PMNs with histamine (H2 receptor agonist), prostaglandin-E1, and isoproterenol (beta-adrenergic receptor agonist).
• Comparison of cAMP responses across drug-free normal controls, patients with schizophrenia, and patients with major depressive disorder (both in exacerbated and remitted states).

Main Results:

• No significant differences were observed in cAMP responses to histamine, prostaglandin-E1, or isoproterenol among the three subject groups.
• Both exacerbated and remitted patients with schizophrenia or major depressive disorder exhibited similar cAMP responses compared to controls.
• The study found no evidence of state-dependent or state-independent alterations in PMN cAMP signaling related to schizophrenia or major depressive disorder.

Conclusions:

• Cyclic adenosine monophosphate (cAMP) responses in polymorphonuclear leukocytes are not suitable biomarkers for diagnosing or monitoring schizophrenia or major depressive disorder.
• The findings indicate that peripheral cAMP signaling pathways, as assessed in PMNs, are not significantly affected by the state of schizophrenia or major depressive disorder.